A shot will lose very little, if any
GLP-1 stimulates insulin secretion, inhibits glucagon release, and reduces appetite, making it a significant target for the management of type 2 diabetes and obesity
SELECT trial: GLP-1 RAs in non-diabetic patients The SELECT trial represented a paradigm shift by evaluating semaglutide exclusively in patients without diabetes
A small study published in 2023 in The Journal of Clinical Psychiatry found that semaglutide helped treat alcohol use disorder in patients who were prescribed the drug for weight loss
doi: 10.1016/j.tcb.2019.02.004
3 Division of Cognitive Neuroscience, Department of Psychology and 4 Transfaculty Research Platform, University of Basel, Basel, Switzerland